Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "putative non-classical estrogen-binding site" refers to various molecular sites, principally located in the plasma membrane, that bind estrogen and mediate signaling independent of classical nuclear estrogen receptors. Notably, this includes G protein-coupled estrogen receptor 1 (GPER1), ER-X, and membrane forms of ERα/ERβ. These sites facilitate rapid, non-genomic signaling events, including modulation of ion channels and second messengers (such as cAMP), leading to transcriptional changes distinct from ERE-mediated gene activation. These mechanisms are implicated in neuroprotection, reproductive tissue development, and diseases including cancer and neurodegeneration. Importantly, the term lacks specificity and is used broadly to encompass a heterogeneous group of proteins and binding sites, of which GPER1 is the best-characterized[2][4][6].
Rapid activation of intracellular second messenger pathways (cAMP, PI3K/Akt, MAPK); Ion channel modulation; Activation of transcription factors not dependent on estrogen response elements (e.g., CREB, AP-1); Membrane-initiated steroid signaling
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Putative non-classical estrogen-binding site.